RNAZ
TransCode Therapeutics, Inc.
Price Chart
Latest Quote
$4.70
-0.65 (-12.15%)
Current Price
| Previous Close | $5.35 |
| Open | $5.29 |
| Day High | $5.45 |
| Day Low | $4.70 |
| Volume | 31,669 |
Stock Information
| Shares Outstanding | 950K |
| Cash Equivalents | $12.84M |
| Net Income | $-43.70M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.47M |
| EPS (TTM) | $-3.71 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $134.90M |
| Income | $-43.70M |
| Book/sh | $11.27 |
| Cash/sh | $13.51 |
| Employees | 12 |
Financial Ratios
| Quick Ratio | 2.39 |
| Current Ratio | 3.11 |
Returns & Margins
| ROA | -17.13% |
| ROE | -52.14% |
Ownership
| Insider Ownership | 8.90% |
| Institutional Ownership | 7.63% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.83 |
| P/B | 0.42 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $5.41 |
| SMA50 | $6.89 |
| SMA200 | $9.15 |
| RSI | 45.08 |
| ATR | 0.7798 |
| Shares Float | 866K |
| Short Float | 2.96% |
| Short Ratio | 2.39 |
| Rel Volume | 0.22 |
Performance History
| Week | -17.40% |
| Month | -23.92% |
| Quarter | -49.52% |
| 6 Months | -48.38% |
| YTD | -36.49% |
| Year | -31.09% |
| 3 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.70 | 31,700 |
| 2026-06-17 | $5.35 | 21,300 |
| 2026-06-16 | $5.54 | 12,100 |
| 2026-06-15 | $5.47 | 38,300 |
| 2026-06-12 | $5.33 | 5,800 |
| 2026-06-11 | $5.69 | 8,400 |
| 2026-06-10 | $5.51 | 18,800 |
| 2026-06-09 | $4.98 | 20,500 |
| 2026-06-08 | $5.09 | 86,200 |
| 2026-06-05 | $5.60 | 99,900 |
| 2026-06-04 | $5.84 | 133,900 |
| 2026-06-03 | $5.04 | 2,328,200 |
| 2026-06-02 | $5.28 | 15,500 |
| 2026-06-01 | $5.43 | 10,300 |
| 2026-05-29 | $5.14 | 8,800 |
| 2026-05-28 | $5.29 | 20,500 |
| 2026-05-27 | $5.09 | 19,900 |
| 2026-05-26 | $5.39 | 40,500 |
| 2026-05-22 | $6.24 | 6,700 |
| 2026-05-21 | $6.11 | 4,700 |
| 2026-05-20 | $6.11 | 15,200 |
| 2026-05-19 | $6.18 | 11,600 |
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
đ° Latest News
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study
Benzinga âĸ 2026-06-03T11:41:41Z
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires âĸ 2025-10-08T19:34:34ZSector Update: Health Care Stocks Advance Wednesday Afternoon
MT Newswires âĸ 2025-10-08T17:42:31ZTransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences
MT Newswires âĸ 2025-10-08T14:54:36ZWall Street Set to Open Higher Wednesday; Dow Rises on Japan Trade Deal
MT Newswires âĸ 2025-07-23T13:16:23Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $6,616 | $26,813 | $55,899 | $31,986 |
| Total Expenses | $17,915,044 | $15,136,633 | $18,495,481 | $17,553,392 |
| Other Income Expense | $-16,592,546 | $-995,252 | - | - |
| Net Non Operating Interest Income Expense | $72,582 | $-623,086 | $-50,614 | $-11,576 |
| Interest Expense Non Operating | $6,616 | $26,813 | $55,899 | $31,986 |
| Operating Expense | $17,915,044 | $15,136,633 | $18,495,481 | $17,553,392 |
| Other Operating Expenses | $-1,277,867 | $-524,064 | $-923,035 | $-1,080,436 |
| General And Administrative Expense | $5,771,063 | $5,954,339 | $7,154,986 | $8,401,462 |
| Total Other Finance Cost | - | $596,957 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-34,661,076 | $-16,754,971 | $-18,546,095 | $-17,564,968 |
| Net Interest Income | $72,582 | $-623,086 | $-50,614 | $-11,576 |
| Interest Income | $79,198 | $684 | $5,285 | $20,410 |
| Normalized Income | $-21,552,965 | $-15,759,719 | $-18,546,095 | $-17,564,968 |
| Net Income From Continuing And Discontinued Operation | $-34,661,076 | $-16,754,971 | $-18,546,095 | $-17,564,968 |
| Total Operating Income As Reported | $-27,980,071 | $-15,660,697 | $-19,418,516 | $-18,633,828 |
| Net Income Common Stockholders | $-36,271,287 | $-16,785,572 | $-18,546,095 | $-17,564,968 |
| Net Income | $-34,661,076 | $-16,754,971 | $-18,546,095 | $-17,564,968 |
| Net Income Including Noncontrolling Interests | $-34,661,076 | $-16,754,971 | $-18,546,095 | $-17,564,968 |
| Net Income Continuous Operations | $-34,661,076 | $-16,754,971 | $-18,546,095 | $-17,564,968 |
| Pretax Income | $-34,435,008 | $-16,754,971 | $-18,546,095 | $-17,564,968 |
| Special Income Charges | $-7,203,160 | $500 | $0 | $0 |
| Interest Income Non Operating | $79,198 | $684 | $5,285 | $20,410 |
| Operating Income | $-17,915,044 | $-15,136,633 | $-18,495,481 | $-17,553,392 |
| Per Share | ||||
| Diluted EPS | $-52.59 | $-1336.63 | $-27313.84 | $-1033233.41 |
| Basic EPS | $-52.59 | $-1336.63 | $-27313.84 | $-1033233.41 |
| Other | ||||
| Tax Effect Of Unusual Items | $-3,484,435 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-17,721,669 | $-15,198,049 | $-17,973,450 | $-17,434,376 |
| Total Unusual Items | $-16,592,546 | $-995,252 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-16,592,546 | $-995,252 | $0 | $0 |
| Reconciled Depreciation | $114,177 | $534,857 | $516,746 | $98,606 |
| EBITDA (Bullshit earnings) | $-34,314,215 | $-16,193,301 | $-17,973,450 | $-17,434,376 |
| EBIT | $-34,428,392 | $-16,728,158 | $-18,490,196 | $-17,532,982 |
| Diluted Average Shares | $689,713 | $12,558 | $679 | $17 |
| Basic Average Shares | $689,713 | $12,558 | $679 | $17 |
| Diluted NI Availto Com Stockholders | $-36,271,287 | $-16,785,572 | $-18,546,095 | $-17,564,968 |
| Otherunder Preferred Stock Dividend | $0 | $30,601 | $0 | - |
| Preferred Stock Dividends | $1,610,211 | - | - | - |
| Tax Provision | $226,068 | $0 | - | - |
| Gain On Sale Of Ppe | $0 | $500 | $0 | $0 |
| Restructuring And Mergern Acquisition | $7,203,160 | $0 | - | - |
| Gain On Sale Of Security | $-9,389,386 | $-995,752 | - | - |
| Research And Development | $13,421,848 | $9,706,358 | $12,263,530 | $10,232,366 |
| Selling General And Administration | $5,771,063 | $5,954,339 | $7,154,986 | $8,401,462 |
| Other Gand A | $5,771,063 | $5,954,339 | $7,154,986 | $8,401,462 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $11,835,859 | $-2,018,734 | $1,640,814 | $3,240,696 |
| Total Assets | $162,398,689 | $7,294,499 | $5,169,701 | $7,587,986 |
| Total Non Current Assets | $140,414,824 | $201,161 | $714,257 | $208,581 |
| Non Current Prepaid Assets | $0 | $111,856 | $111,856 | $0 |
| Goodwill And Other Intangible Assets | $140,044,143 | $0 | - | - |
| Other Intangible Assets | $114,300,000 | - | - | - |
| Current Assets | $21,983,865 | $7,093,338 | $4,455,444 | $7,379,405 |
| Other Current Assets | $2,826,846 | $828,219 | $1,148,747 | $1,496,428 |
| Prepaid Assets | $390,400 | $454,055 | $539,099 | $554,330 |
| Receivables | $953,098 | $0 | $0 | $360,229 |
| Other Receivables | $952,460 | - | - | $360,229 |
| Cash Cash Equivalents And Short Term Investments | $17,813,521 | $5,811,064 | $2,767,598 | $4,968,418 |
| Cash And Cash Equivalents | $17,813,521 | $5,811,064 | $2,767,598 | $4,968,418 |
| Cash Financial | $17,813,521 | $5,811,064 | $2,767,598 | $4,968,418 |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $0 | $38,291 | $450,571 | $0 |
| Long Term Debt And Capital Lease Obligation | - | $0 | $38,291 | $0 |
| Current Debt And Capital Lease Obligation | - | $38,291 | $412,280 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,518,687 | $9,313,233 | $3,528,887 | $4,347,290 |
| Total Non Current Liabilities Net Minority Interest | $7,024,467 | $6,541,397 | $38,291 | $0 |
| Other Non Current Liabilities | $6,364,000 | - | - | - |
| Derivative Product Liabilities | $434,399 | $6,541,397 | $0 | - |
| Non Current Deferred Liabilities | $226,068 | $0 | - | - |
| Non Current Deferred Taxes Liabilities | $226,068 | $0 | - | - |
| Current Liabilities | $3,494,220 | $2,771,836 | $3,490,596 | $4,347,290 |
| Current Deferred Liabilities | $0 | $25,408 | $27,057 | $0 |
| Payables And Accrued Expenses | $3,494,220 | $2,708,137 | $3,051,259 | $4,347,290 |
| Equity | ||||
| Common Stock Equity | $10,335,466 | $-2,018,734 | $1,640,814 | $3,240,696 |
| Preferred Stock Equity | $141,544,536 | - | - | - |
| Total Equity Gross Minority Interest | $151,880,002 | $-2,018,734 | $1,640,814 | $3,240,696 |
| Stockholders Equity | $151,880,002 | $-2,018,734 | $1,640,814 | $3,240,696 |
| Retained Earnings | $-97,862,992 | $-63,201,916 | $-46,416,344 | $-27,870,249 |
| Preferred Securities Outside Stock Equity | $141,544,536 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $916,968 | $36,753 | $679 | $17 |
| Share Issued | $916,968 | $36,753 | $679 | $17 |
| Tangible Book Value | $-129,708,677 | $-2,018,734 | $1,640,814 | $3,240,696 |
| Invested Capital | $10,335,466 | $-2,018,734 | $1,640,814 | $3,240,696 |
| Working Capital | $18,489,645 | $4,321,502 | $964,848 | $3,032,115 |
| Capital Lease Obligations | $0 | $38,291 | $450,571 | $0 |
| Total Capitalization | $151,880,002 | $-2,018,734 | $1,640,814 | $3,240,696 |
| Additional Paid In Capital | $108,198,366 | $61,183,178 | $48,057,156 | $31,110,943 |
| Capital Stock | $141,544,628 | $4 | $2 | $2 |
| Common Stock | $92 | $4 | $2 | $2 |
| Preferred Stock | $141,544,536 | $0 | $0 | $0 |
| Current Deferred Revenue | $0 | $25,408 | $27,057 | $0 |
| Current Capital Lease Obligation | $0 | $38,291 | $412,280 | $0 |
| Current Accrued Expenses | $3,494,220 | $2,708,137 | $3,051,259 | $4,347,290 |
| Goodwill | $25,744,143 | $0 | - | - |
| Net PPE | $370,681 | $89,305 | $602,401 | $208,581 |
| Accumulated Depreciation | $-387,260 | $-310,813 | $-263,343 | $-139,860 |
| Gross PPE | $757,941 | $400,118 | $865,744 | $348,441 |
| Machinery Furniture Equipment | $757,941 | $362,387 | $384,050 | $348,441 |
| Duefrom Related Parties Current | $638 | $0 | - | - |
| Long Term Capital Lease Obligation | - | $0 | $38,291 | $0 |
| Other Properties | - | $37,731 | $481,694 | - |
| Treasury Shares Number | - | - | $0 | - |
| Non Current Accrued Expenses | - | - | - | - |
| Dueto Related Parties Current | - | - | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-19,522,889 | $-13,357,708 | $-18,110,144 | $-15,863,431 |
| Operating Activities | ||||
| Operating Cash Flow | $-19,516,229 | $-13,335,947 | $-18,074,535 | $-15,762,512 |
| Cash Flow From Continuing Operating Activities | $-19,516,229 | $-13,335,947 | $-18,074,535 | $-15,762,512 |
| Operating Gains Losses | $9,277,321 | $1,535,647 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-6,660 | $-21,761 | $-35,609 | $-100,919 |
| Investing Cash Flow | $-4,436 | $-21,761 | $-35,609 | $-100,919 |
| Cash Flow From Continuing Investing Activities | $-4,436 | $-21,761 | $-35,609 | $-100,919 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $31,523,122 | $16,401,174 | $15,909,324 | $0 |
| Financing Cash Flow | $31,523,122 | $16,401,174 | $15,909,324 | $5,989 |
| Cash Flow From Continuing Financing Activities | $31,523,122 | $16,401,174 | $15,909,324 | $5,989 |
| Net Preferred Stock Issuance | $22,668,324 | $0 | - | - |
| Preferred Stock Issuance | $22,668,324 | $0 | - | - |
| Net Common Stock Issuance | $8,854,798 | $16,401,174 | $15,909,324 | $0 |
| Common Stock Issuance | $8,854,798 | $16,401,174 | $15,909,324 | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Interest Paid Supplemental Data | $6,501 | $16,629 | $32,861 | $37,115 |
| End Cash Position | $17,813,521 | $5,811,064 | $2,767,598 | $4,968,418 |
| Beginning Cash Position | $5,811,064 | $2,767,598 | $4,968,418 | $20,825,860 |
| Changes In Cash | $12,002,457 | $3,043,466 | $-2,200,820 | $-15,857,442 |
| Net Business Purchase And Sale | $2,224 | $0 | - | - |
| Sale Of Business | $2,224 | $0 | - | - |
| Net PPE Purchase And Sale | $-6,660 | $-21,761 | $-35,609 | $-100,919 |
| Purchase Of PPE | $-6,660 | $-21,761 | $-35,609 | $-100,919 |
| Change In Working Capital | $15,567 | $-351,479 | $-1,082,075 | $1,308,521 |
| Change In Other Working Capital | $200,660 | $-1,649 | $27,057 | $-30,528 |
| Change In Other Current Liabilities | $-38,291 | $-412,280 | $-424,385 | $0 |
| Change In Other Current Assets | $111,856 | $0 | $-111,856 | $0 |
| Change In Payables And Accrued Expense | $216,541 | $-343,123 | $-1,296,032 | $1,843,722 |
| Change In Prepaid Assets | $477,261 | $405,573 | $362,912 | $-144,444 |
| Change In Receivables | $-952,460 | $0 | $360,229 | $-360,229 |
| Other Non Cash Items | $5,252,354 | - | - | - |
| Stock Based Compensation | $485,428 | $1,699,999 | $1,036,889 | $395,329 |
| Depreciation Amortization Depletion | $114,177 | $534,857 | $516,746 | $98,606 |
| Depreciation And Amortization | $114,177 | $534,857 | $516,746 | $98,606 |
| Depreciation | $114,177 | $534,857 | $516,746 | $98,606 |
| Gain Loss On Investment Securities | $9,277,321 | $1,535,647 | - | - |
| Net Income From Continuing Operations | $-34,661,076 | $-16,754,971 | $-18,546,095 | $-17,564,968 |
| Proceeds From Stock Option Exercised | - | - | $0 | $5,989 |
| Sale Of PPE | - | - | - | $0 |
| Change In Accrued Expense | - | - | - | $0 |
| Change In Interest Payable | - | - | - | $0 |
| Change In Payable | - | - | - | $1,843,722 |
| Change In Account Payable | - | - | - | $1,843,722 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Income Tax Paid Supplemental Data | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-19